Sign inJoin waitlistJoin the waitlist

Sara Zarnegar-Lumley

Medical Director, Hematological Malignancy Program · McGaw Medical Center of Northwestern University

Credentials: · · · ·

History

Hematological Malignancy Program · McGaw Medical Center of Northwestern University
Present
McGaw Medical Center of Northwestern University
Present

Memorial Sloan Kettering Cancer Center
2014–2017
Pediatrics
McGaw Medical Center of Northwestern University
2011–2014
Georgetown University School of Medicine
2007–2011

Research

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
Proceedings of the National Academy of Sciences of the United States of America · 2005 · 263 citations
Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy
Human Molecular Genetics · 2002 · 76 citations
Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy
Journal of Clinical Investigation · 2004 · 61 citations

Debra Friedman
4 papers
Elizabeth McNally
3 papers
Erin Rowell
3 papers
Jessica Pollard
3 papers
Matthew Kutny
3 papers
Matthew Wheeler
3 papers
Andrew Bukowinski
2 papers
Anthony Audino
2 papers
Barbara Lockart
2 papers
Cosby Stone
2 papers
Elizabeth Phillips
2 papers
Grace Koo
2 papers · 2 as a fellow

Clinical trials

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Principal investigator · Active not recruiting · Phase 2
Children's Oncology Group
2023–2026
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2033
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Site PI · Recruiting · Phase 1
Children's Oncology Group
2025–2028